Key points from article :
Rubedo Life Sciences secured a funding of 12 million to develop senolytic therapies.
Now conducting preparatory work for IND-enabling studies, ahead of moving to Phase 1 clinical trial.
Want to customise new medicines for elderly & target the main biological events behind ageing.
“We are not a senolytic company, per se,” - Dr Marco Quarta, Rubedo’s CEO and co-founder.
“Our first and most advanced programme is our senolytic programme, but our Alembic platform is agnostic.”
"Alembic allows us to identify novel targets & use this information to design and engineer more molecules.”
Lung disease was definitely the space they wanted to move on first even before the pandemic.
With COVID-19 expected to accelerate the ageing process of survivors’ lung tissue - Rubedo’s work can benefit people.
